Belpointe Asset Management LLC Sells 4,134 Shares of Danaher Corporation $DHR

Key Points

• Belpointe Asset Management LLC has reduced its stake in Danaher Corporation by 46.7%, selling 4,134 shares and retaining 4,713 shares valued at approximately $966,000.
• Danaher recently reported $1.80 earnings per share (EPS) for the quarter, exceeding analysts' expectations, with revenue reaching $5.94 billion, reflecting a 3.4% year-over-year increase.
• The company plans to pay a quarterly dividend of $0.32 per share on October 31st, with a yield of 0.7% based on an annualized basis.

Belpointe Asset Management LLC lessened its stake in Danaher Corporation (NYSE:DHR - Free Report) by 46.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,713 shares of the conglomerate's stock after selling 4,134 shares during the period. Belpointe Asset Management LLC's holdings in Danaher were worth $966,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of DHR. Intech Investment Management LLC raised its position in shares of Danaher by 46.8% during the 1st quarter. Intech Investment Management LLC now owns 14,591 shares of the conglomerate's stock valued at $2,991,000 after acquiring an additional 4,653 shares during the last quarter. Focus Partners Wealth raised its position in shares of Danaher by 10.7% during the 1st quarter. Focus Partners Wealth now owns 196,682 shares of the conglomerate's stock valued at $40,328,000 after acquiring an additional 19,086 shares during the last quarter. Flaharty Asset Management LLC bought a new stake in shares of Danaher during the 1st quarter valued at $88,000. Integrity Alliance LLC. raised its position in shares of Danaher by 191.4% during the 1st quarter. Integrity Alliance LLC. now owns 4,831 shares of the conglomerate's stock valued at $990,000 after acquiring an additional 3,173 shares during the last quarter. Finally, Ransom Advisory Ltd bought a new stake in shares of Danaher during the 1st quarter valued at $536,000. Institutional investors own 79.05% of the company's stock.

Analyst Ratings Changes

DHR has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Barclays reiterated an "overweight" rating and set a $225.00 target price (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a research report on Friday, July 11th. UBS Group decreased their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Finally, Evercore ISI lowered their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $246.35.

Danaher Price Performance

DHR opened at $195.23 on Friday. The company has a fifty day simple moving average of $201.47 and a 200 day simple moving average of $199.04. The stock has a market cap of $139.79 billion, a P/E ratio of 41.54, a P/E/G ratio of 2.69 and a beta of 0.75. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is 27.23%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.